Literature DB >> 24342774

Social interaction and social withdrawal in rodents as readouts for investigating the negative symptoms of schizophrenia.

Christina A Wilson1, James I Koenig2.   

Abstract

Negative symptoms (e.g., asociality and anhedonia) are a distinct symptomatic domain that has been found to significantly affect the quality of life in patients diagnosed with schizophrenia. Additionally, the primary negative symptom of asociality (i.e., withdrawal from social contact that derives from indifference or lack of desire to have social contact) is a major contributor to poor psychosocial functioning and has been found to play an important role in the course of the disorder. Nonetheless, the pathophysiology underlying these symptoms is unknown and currently available treatment options (e.g., antipsychotics and cognitive-behavioral therapy) fail to reliably produce efficacious benefits. Utilizing rodent paradigms that measure social behaviors (e.g., social withdrawal) to elucidate the neurobiological substrates that underlie social dysfunction and to identify novel therapeutic targets may be highly informative and useful to understand more about the negative symptoms of schizophrenia. Accordingly, the purpose of this review is to provide an overview of the behavioral tasks for assessing social functioning that may be translationally relevant for investigating negative symptoms associated with schizophrenia.
© 2013 Published by Elsevier B.V. and ECNP.

Entities:  

Keywords:  Negative symptoms; Rodent model; Schizophrenia; Social interaction; Social withdrawal

Mesh:

Substances:

Year:  2013        PMID: 24342774      PMCID: PMC4481734          DOI: 10.1016/j.euroneuro.2013.11.008

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  152 in total

Review 1.  The neurobiology of social cognition.

Authors:  R Adolphs
Journal:  Curr Opin Neurobiol       Date:  2001-04       Impact factor: 6.627

Review 2.  Animal models of neuropsychiatric disorders.

Authors:  Eric J Nestler; Steven E Hyman
Journal:  Nat Neurosci       Date:  2010-09-27       Impact factor: 24.884

3.  The NIMH-MATRICS consensus statement on negative symptoms.

Authors:  Brian Kirkpatrick; Wayne S Fenton; William T Carpenter; Stephen R Marder
Journal:  Schizophr Bull       Date:  2006-02-15       Impact factor: 9.306

Review 4.  Catecholamines in the brain as mediators of amphetamine psychosis.

Authors:  S H Snyder
Journal:  Arch Gen Psychiatry       Date:  1972-08

5.  Automation of the social interaction test by a video-tracking system: behavioural effects of repeated phencyclidine treatment.

Authors:  F Sams-Dodd
Journal:  J Neurosci Methods       Date:  1995-07       Impact factor: 2.390

6.  Effect of cannabidiol in a MK-801-rodent model of aspects of schizophrenia.

Authors:  Anand Gururajan; David Alan Taylor; Daniel Thomas Malone
Journal:  Behav Brain Res       Date:  2011-03-31       Impact factor: 3.332

7.  Neuropsychological impairment and psychopathology in first-episode schizophrenic patients related to the early course of illness.

Authors:  J Binder; M Albus; W Hubmann; J Scherer; N Sobizack; U Franz; F Mohr; S Hecht
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1998       Impact factor: 5.270

Review 8.  Oxytocin, vasopressin and sociality.

Authors:  C Sue Carter; Angela J Grippo; Hossein Pournajafi-Nazarloo; Michael G Ruscio; Stephen W Porges
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

Review 9.  The role of the cerebellum in schizophrenia: from cognition to molecular pathways.

Authors:  Peyman Yeganeh-Doost; Oliver Gruber; Peter Falkai; Andrea Schmitt
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

10.  Affiliative behavior, ultrasonic communication and social reward are influenced by genetic variation in adolescent mice.

Authors:  Jules B Panksepp; Kimberly A Jochman; Joseph U Kim; Jamie J Koy; Ellie D Wilson; Qiliang Chen; Clarinda R Wilson; Garet P Lahvis
Journal:  PLoS One       Date:  2007-04-04       Impact factor: 3.240

View more
  32 in total

1.  Effects of fingolimod administration in a genetic model of cognitive deficits.

Authors:  D Becker-Krail; A Q Farrand; H A Boger; A Lavin
Journal:  J Neurosci Res       Date:  2016-07-20       Impact factor: 4.164

2.  Haloperidol rescues the schizophrenia-like phenotype in adulthood after rotenone administration in neonatal rats.

Authors:  Thiago Garcia Varga; Juan Guilherme de Toledo Simões; Amanda Siena; Elisandra Henrique; Regina Cláudia Barbosa da Silva; Vinicius Dos Santos Bioni; Aline Camargo Ramos; Tatiana Rosado Rosenstock
Journal:  Psychopharmacology (Berl)       Date:  2021-06-05       Impact factor: 4.530

3.  Anxiety does not contribute to social withdrawal in the subchronic phencyclidine rat model of schizophrenia.

Authors:  Alexandre Seillier; Andrea Giuffrida
Journal:  Behav Pharmacol       Date:  2017-10       Impact factor: 2.293

Review 4.  Preclinical Models to Investigate Mechanisms of Negative Symptoms in Schizophrenia.

Authors:  Samuel A Barnes; Andre Der-Avakian; Jared W Young
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

5.  Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.

Authors:  O J Onaolapo; T B Paul; A Y Onaolapo
Journal:  Metab Brain Dis       Date:  2017-05-15       Impact factor: 3.584

6.  Decreasing GABA function within the medial prefrontal cortex or basolateral amygdala decreases sociability.

Authors:  Tracie A Paine; Nathan Swedlow; Lucien Swetschinski
Journal:  Behav Brain Res       Date:  2016-10-11       Impact factor: 3.332

7.  Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model.

Authors:  Ashleigh L Osborne; Nadia Solowij; Ilijana Babic; Xu-Feng Huang; Katrina Weston-Green
Journal:  Neuropsychopharmacology       Date:  2017-02-23       Impact factor: 7.853

8.  Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3β/β-catenin pathway.

Authors:  Hebatalla I Ahmed; Somaia A Abdel-Sattar; Heba S Zaky
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-06       Impact factor: 3.000

Review 9.  Developmental vitamin D deficiency and schizophrenia: the role of animal models.

Authors:  S A Schoenrock; L M Tarantino
Journal:  Genes Brain Behav       Date:  2016-01       Impact factor: 3.449

10.  Disruption of social cognition in the sub-chronic PCP rat model of schizophrenia: Possible involvement of the endocannabinoid system.

Authors:  Alexandre Seillier; Andrea Giuffrida
Journal:  Eur Neuropsychopharmacol       Date:  2015-12-10       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.